PROS1 and COVID-19: There are several preclinical reports using saRNA vectors to develop COVID-19 vaccine candidates5–10 expressing full length S protein, and these candidate vaccines induced high humoral and cellular responses as well as protection against COVID-19 challenge in animal models.